Ulcerative Colitis

CTAF

Due to the COVID-19 pandemic, ICER will publish its UC Draft Evidence Report on April 15. All additional deadlines and public input opportunities will be pushed back approximately 2-3 months.


ICER will assess the comparative clinical effectiveness and value of therapies for ulcerative colitis (UC), including:

  • Vedolizumab (Entyvio®, Takeda), subcutaneous and IV formulations
  • Infliximab (Remicade®, Janssen)
  • Infliximab-dyyb (Inflectra®, Pfizer)
  • Infliximab-abda (Renflexis®, Merck)
  • Adalimumab (Humira®, AbbVie)
  • Golimumab (Simponi®, Janssen)
  • Tofacitinib (Xeljanz®, Pfizer)
  • Ustekinumab (Stelara®, Janssen)

Date of Review: September 2020

For questions, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer-review.org.

Associated Meetings

September 24, 2020 10am-4pm PT
TBA

The CTAF will convene to deliberate and vote on evidence presented in ICER's report on ulcerative colitis therapies.


Key Dates

Associated Materials

09/06/2019 – 09/24/2019
Open Input Period

09/27/2019

09/27/2019 – 10/18/2019

09/27/2019

11/04/2019

12/11/2019

02/03/2020

04/15/2020
Draft Evidence Report

04/15/2020
Draft Voting Questions

04/15/2020 – 07/29/2020
Public Comments

09/02/2020
Revised Voting Questions

09/02/2020
Response to Public Comments

09/02/2020
Evidence Report

09/24/2020
Meeting Agenda

09/24/2020
Evidence Presentation

10/16/2020
Final Policy Recommendations

10/16/2020
Final Evidence Report and Meeting Summary

10/16/2020
Report-at-a-Glance